Verastem Oncology says RAMP 201 analysis shows 18% ORR for avutometinib-defactinib in triple wild-type recurrent LGSOC
Bitget2026/10/02 11:30- Verastem Oncology outlined new analyses from its Phase 2 RAMP 201 study of avutometinib with defactinib in recurrent LGSOC.
- Results will be presented at the IGCS 2026 meeting in Montréal on Oct. 2, 2026.
- Molecular profiling showed the regimen produced meaningful responses in KRAS wild-type disease, including tumors lacking KRAS, NRAS, BRAF mutations.
- An external control analysis indicated better tumor response and longer disease control versus conventional chemotherapy or anti-estrogen care.
- Data reinforced the regimen’s role in KRAS-mutated first-recurrence LGSOC, supporting expansion efforts in KRAS wild-type patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Selloff Sends Berkshire to Its Biggest S&P 500 Lead Since 2010: Can It Last?
Meridian weighs $400 million investment decision for Cabaçal mine
Saudi Arabia's oil production in October surged by 26%, reaching the highest level since the onset of the conflict, while Brent crude has dropped over 20% this month
OPEC's monthly report shows that Saudi Arabia's average daily crude oil production in October rose to 10.56 million barrels, just several hundred thousand barrels lower than the pre-war level in February and slightly above its quoted limit under the OPEC framework. Iraq's daily output in October also reached approximately 4.9 million barrels, a new high since the outbreak of war. Meanwhile, after the UAE exited OPEC and began competing in the market independently, both the UAE and Saudi Arabia recently slashed their official December cargo prices for Asian buyers, intensifying the competitive landscape.
Scorpio hits gold beyond Nevada resource
Crypto prices
More
